CountryAfghanistanAlbaniaAlgeriaAndorraAngolaAntigua & BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia & HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaComorosCongoCongo Democratic RepublicCosta RicaCote d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEast TimorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKorea NorthKorea SouthKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalThe NetherlandsNew ZealandNicaraguaNigerNigeriaNorwayOmanPakistanPalauPalestinian State*PanamaPapua New GuineaParaguayPeruThe PhilippinesPolandPortugalQatarRomaniaRussiaRwandaSt. Kitts & NevisSt. LuciaSt. Vincent & The GrenadinesSamoaSan MarinoSao Tome & PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth SudanSpainSri LankaSudanSurinameSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad & TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States of AmericaUruguayUzbekistanVanuatuVatican City (Holy See)VenezuelaVietnamYemenZambiaZimbabwe
Multi User License - $2,500
Despite the fact that the Indian pharmaceutical business has traditionally relied heavily on manual labour, it is rapidly embracing automated technology. To remain competitive in a linked world, it is currently using new automated operational technology (OT) and information technology (IT).
Companies in this area, both local and global, will succeed in meeting today’s problems only via continual innovation and the prudent embrace of new technology.
Global regulatory compliance; quality concerns; inconsistent manual production workflows; human mistakes; cost challenges; and increased global rivalry are some of problems.
Given India’s continued dominance in IT services, pharmaceutical businesses could use this local experience to modernise processes and integrate new Industrial Internet of Things (IIoT)-related technologies and methodologies such as smart sensors, Big Data, predictive analytics, and cloud computing.
These might improve R&D, manufacturing, and regulatory compliance, in addition to helping to improve the patient experience through linked healthcare. Significantly, the deployment of these technologies necessitates the collaboration of different skill sets, sectors, and domains.
The India pharmacy automation market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2026, registering a CAGR of XX% from 2022 to 2027.
Cipla is embarking on a strategic ‘Reimagination’ journey, with the goal of developing several dimensions of automated equipment, data-driven decision making and performance increases and becoming a digitally native company with at-scale digital analytics capabilities.
Because of the epidemic, organisations must become more flexible and responsive to the new normal in the short and long term.
To address this changing environment, Cipla is embarking on a strategic ‘Reimagination’ journey, headed by the digital transformation of their value chain spanning functions such as Finance, R&D, Manufacturing, Supply Chain, HR, Customer Outreach, and Stakeholder Engagement.
They have conducted as part of this re-imagination effort, which is assisting the organisation in attaining a top industry position in terms of quality, cost, productivity, and service standards.
© Copyright 2017-2022. Mobility Foresights. All Rights Reserved.